CP: #ThérapiesCellulaires: @treefrogtx passe à la fabrication industrielle grâce à une nouvelle machine aux normes BPF! Next : Transfert #CDMO en 2023. Essai clinique #Parkinson en 2024. Et 3 nouveaux encapsulateurs livrés en 2023 pour accélérer! #FT120 https://t.co/xorC4E2X52
"Scaling-up iPSC-based cell therapies: towards clinical grade processes with biomimetic C-Stem technology"
Next Wednesday, don't miss Senior Application Scientist Odette Becheau oral presentation at the BELSACT Scientific Meeting in #Leuven.
Do not hesitate to connect with her!
We get this question a lot: Can you #differentiate#pluripotent#stemcells into any cell type in C-Stem™-generated alginate capsules?
Here a quick answer. Link to our latest paper on #iPSC expansion, with some trilineage data (Fig. 3): https://t.co/wvB6NR6BzE
After the largest, longest ph 3 of any CAR-T #celltherapy, @KitePharma's
Yescarta is the 1st treatment in nearly 30 yrs to show stat significant improvement in OS for initial treatment of relapsed/refractory large B-cell lymphoma versus historical SOC. https://t.co/t2s0iRXSPa
@treefrogtx' co-founder and CSO Maxime Feyeux will give a talk on scale-up at @JSRM_Official meeting (March 24).
Do not hesitate to connect with him on-site or during his 2-week trip through Tokyo, Kyoto, Kobe, Osaka and Fukuoka, from March 20th to April 1st.
#celltherapyforall
The @treefrogtx alginate encapsulation system efficiency could be due to its ability to recapitulate in capsulo a 3D lumenized colony that morphologically resembles an epiblast rosette, and which has higher cell viability than 2D colonies.
https://t.co/5npPuffGw9
Following our recent paper describing #hiPSC#ScaleUp in #10L#bioreactors, our CSO highlights how the C-Stem™ platform can impact the manufacturing of stem cell-derived therapies.
More videos answering frequently asked questions about C-Stem™ : https://t.co/OAM0sAKkfy
What does the C-Stem™ platform bring to the #CellTherapy field? For once I am the one answering questions in this short video about our latest paper in #Biomaterials. 5 other videos addressing FAQS about C-Stem are online: https://t.co/dRAV0bo6Yw
Happening live TOMORROW! ⚠️ This is your last chance to sign for this webinar on #pluripotent stem cells with Dr. Maxime Feyeux (@FeyeuxMaxime): https://t.co/AlFUg5SGgp
What can the human body 🧍 teach us about how to scale up high-quality #pluripotent stem cells (PSCs)?
Join us for a live webinar on March 7, with Dr. Maxime Feyeux (@FeyeuxMaxime), co-founder of TreeFrog Therapeutics (@treefrogtx), to find out. https://t.co/BaTBLkkDUR
3/6 Gaia Biomedicine & @treefrogtx announce collaboration for the expansion of allogeneic NK-like cells against solid tumors. https://t.co/0cLpgSbN2U
Releasing a #whitepaper on the lumenized rosette - the 3D conformation adopted by human #PluripotentStemCells in vivo !
Properties / PSC growth & quality / comparison with 2D/aggregates / Biomimetic PSC culture in large-scale bioreactors
Download : https://t.co/s8g08vzqwq
TreeFrog dans le #FT120 !
Quelle trajectoire ? Quels jalons à venir ? Quel impact en France ?
2 min avec Jean-Luc TREILLOU, co-fondateur de @treefrogtx.
Bienvenue aux nouveaux entrants dans le FrenchTech120, et un grand merci à @LaFrenchTech !
What to find on our new scientific blog ?
#1 Exclusive & free resources: a list of #CellTherapy#trials based on #Pluripotent#StemCells, a white paper on the lumenized rosette – the specific 3D conformation adopted by hPSCs in vivo, interviews... https://t.co/OAM0sAKkfy
Press Release : Clinical-stage Japanese biotech Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors. Full press release: https://t.co/hWtnqPHuPI
@treefrogtx team will start 2023 in #SanFrancisco !
Frédéric Desdouits and Kévin Alessandri will attend the J.P. Morgan 41st annual Healthcare Meeting from January 9th to 12th 2023.
Feel free to reach out to schedule a meeting.
#JPMorgan#celltherapyforall
Meet us next week at iPSC-Derived Cell Therapies Summit, from December 6th to 7th in Boston !
Feel free to connect with our Boston team, CTO Kévin Alessandri and BD Officer Anthony Renodon, based in @LabCentral (@MassBio).
#Boston#celltherapyforall